Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06750289 · ClinicalTrials.gov registry record · Phase 3

Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment

A Phase 3 study of Eosinophilic Asthma, sponsored by AstraZeneca.

Recruiting
Registry status
Phase 3
Development phase
400
Enrollment target
20
Study locations

NCT06750289 is a Phase 3 study of Eosinophilic Asthma that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 400 participants, below the 472-participant average among 4 other Eosinophilic Asthma trials with a reported enrollment target (15% lower). The trial reports 20 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06750289, a Phase 3 study of Eosinophilic Asthma, is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status
Phase 3
Development phase
400 participants
Enrollment target
20
Study locations

Study Summary

This study evaluates the efficacy and safety of benralizumab as an add-on therapy in uncontrolled eosinophilic asthma participants treated with medium-dose ICS-LABA compared to the conventional treatment step of escalation of inhaled therapy to high-dose ICS-LABA.

Conditions Studied

Eosinophilic Asthma

Interventions

  • COMBINATION_PRODUCT ICS-LABA
  • COMBINATION_PRODUCT benralizumab
  • COMBINATION_PRODUCT Placebo for Benralizumab

Study Locations (20)

Florida

  • Research Site - Cape Coral
  • Research Site - Hialeah
  • Research Site - Lauderdale Lakes
  • Research Site - Leesburg
  • Research Site - Miami
  • Research Site - Miami
  • Research Site - Miami
  • Research Site - Orlando
  • Research Site - Plantation
  • Research Site - Tampa
  • Research Site - Winter Park

California

  • Research Site - Bakersfield
  • Research Site - Inglewood
  • Research Site - Modesto
  • Research Site - Newport Beach
  • Research Site - Pasadena

Arizona

  • Research Site - Chandler
  • Research Site - Sun City
  • Research Site - Tucson

Colorado

  • Research Site - Denver

Trial Details

FieldValue
Enrollment Target 400 participants
Start Date 2025-03-28
Est. Completion 2027-11-03
Phase Phase 3

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06750289

The ClinicalTrials.gov registry entry for NCT06750289 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 472-participant average among 4 other Eosinophilic Asthma trials with a reported enrollment target (15% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Eosinophilic Asthma appearing as the primary indexed condition, and to 3 interventions - of which ICS-LABA is the first listed.

NCT06750289 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Florida, California, Arizona.

Frequently Asked Questions

What is clinical trial NCT06750289 about?

NCT06750289 is a clinical study titled "Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment". This study evaluates the efficacy and safety of benralizumab as an add-on therapy in uncontrolled eosinophilic asthma participants treated with medium-dose ICS-LABA compared to the conventional treatment step of escalation of inhaled therapy to high-dose ICS-LABA.

What is the current status of trial NCT06750289?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 400 participants. The study started on 2025-03-28. Estimated completion is 2027-11-03.

What conditions does trial NCT06750289 study?

This clinical trial studies the following conditions: Eosinophilic Asthma.

What interventions are being tested in trial NCT06750289?

The interventions under investigation include: ICS-LABA (COMBINATION_PRODUCT), benralizumab (COMBINATION_PRODUCT), Placebo for Benralizumab (COMBINATION_PRODUCT).

Who is sponsoring clinical trial NCT06750289?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06750289 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Eosinophilic Asthma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Eosinophilic Asthma

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.